Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW +5.36%80 EV-to-EBIT is -170.16 as of Aug. 19, 2026. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 684 Drug Manufacturers companies, Harrow ranks worse than 146198.68% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Harrow's Enterprise Value is $1,777.5 Mil.
Harrow's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-10.4 Mil. Therefore, Harrow's EV-to-EBIT for today is -170.16.
The historical rank and industry rank for Harrow's EV-to-EBIT or its related term are showing as below:
HROW'
s EV-to-EBIT Range Over the Past 10 Years
Min: -587.39 Med: -4.86 Max: 532.4
Current: -170.16
During the past 13 years, the highest EV-to-EBIT of Harrow was 532.40. The lowest was -587.39. And the median was -4.86.
HROW's EV-to-EBIT is ranked worse than 100% of 684
companies
in the Drug Manufacturers industry
Industry Median: 15.685
vs HROW: -170.16
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Harrow's Enterprise Value for the quarter that ended in Jun. 2026 was $1,808.4 Mil.
Harrow's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow EV-to-EBIT Related Terms
Harrow EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Harrow's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Harrow's EV-to-EBIT falls into.
Harrow's current Enterprise Value is $1,777.5 Mil.
Harrow's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow (HROW) has a EV-to-EBIT of -170.16 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Harrow and its competitors. According to the industry distribution chart, Harrow ranks #999999 out of 684 companies in the Drug Manufacturers industry.
Is Harrow's EV-to-EBIT too high?
Harrow's current EV-to-EBIT is -170.16. Based on the distribution chart, Harrow ranks #999999 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's EV-to-EBIT compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #999999 out of 684 companies for EV-to-EBIT. This places Harrow in the lower half of its industry. The industry median EV-to-EBIT is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current EV-to-EBIT is -170.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.63 — trading 0.9% below its estimated fair value. The current EV-to-EBIT is -170.16. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Harrow (HROW), the current EV-to-EBIT is -170.16 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.63 is trading 0.9% below its estimated GF Value™ of $42.00.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
EV-to-EBIT: -170.16
GF Value™: $42.00 vs. price of $41.63 (0.9% below fair value)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score
Get the complete analysis for HROW
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
